SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is currently the focus of intense market attention as investors brace for the upcoming FDA advisory committee meeting regarding its Duchenne muscular dystrophy therapy. The community is heavily debating the regulatory path forward, with significant focus on the potential for a dual-label approval and the implications of recent statistical analyses on the therapy's overall efficacy.

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SPCX is facing intense downward pressure as investors grow increasingly cautious ahead of a major insider share lockup expiration in early August, fueling community debate about the company's valuation versus its long-term growth potential. While some market participants are aggressively betting on a short squeeze due to oversold conditions, many community members remain skeptical, pointing to the risk of increased selling supply and questioning the timeline for reaching profitability.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending as investors weigh an expanded commercial agreement with AT&T against broader macro-driven volatility in high-beta tech stocks. While the community is actively debating the stock's fundamental potential and upcoming earnings, sentiment remains divided between those viewing the recent pullback as a buying opportunity and others concerned about valuation in a tightening market.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp (SNDK) is experiencing intense volatility and downward pressure as market participants debate the impact of rising competition from Chinese memory manufacturers and broader concerns regarding semiconductor sector valuations. While some investors are aggressively accumulating shares, viewing the selloff as a temporary correction ahead of upcoming earnings, others are deeply skeptical and point to a lack of clear support levels as a sign of a potential larger structural rotation.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is capturing market attention following the announcement of a massive AI infrastructure partnership with SK Group and ongoing discussions regarding a multi-billion dollar financing backstop for OpenAI's data center projects. Investors are actively debating the sustainability of this circular financing model and the broader implications for AI-driven capital expenditures, leading to high volatility and conflicting sentiment among both bulls and short-sellers.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is capturing investor attention following a series of executive orders aimed at accelerating U.S. quantum technology leadership and secure data migration. The community is actively debating the stock's long-term potential as a pure-play hardware entity, weighing positive government collaboration against concerns regarding cash burn rates and valuation volatility.

Fundrise Innovation Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is trending as investors react to an accelerated lockup expiration, heightening concerns over the fund's heavy premium to NAV and its significant exposure to private AI and aerospace unicorns like Anthropic and SpaceX. Community discourse is sharply divided between retail bulls who view the fund as a rare entry point into transformative AI companies and bears highlighting the fund's structure as a closed-end fund trading at an extreme valuation.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corp - ADR

Legend Biotech

Legend Biotech is facing intense volatility driven by market concerns regarding competitive pressure from new multiple myeloma treatments and broader leadership transitions. The community remains deeply divided, with some investors leveraging the price drop as a potential buy-in opportunity for long-term buyout prospects, while others express frustration over management optics and the impact of institutional downgrades.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is currently drawing significant investor interest as it navigates volatility, with the community closely tracking its role as a critical supply chain partner in the booming AI infrastructure and hyperscaler hardware sector. Despite recent price swings, discussions remain heavily focused on its strong growth outlook, effective earnings execution, and potential for a re-rating as hyperscalers continue to scale data center capital expenditures.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending as investors weigh strong US sales momentum and upcoming J-code reimbursement against concerns regarding off-label competition from AstraZeneca's Ultomiris. The community is actively discussing management's recent convertible debt buybacks as a sign of confidence while debating the impact of executive departures and the urgency of upcoming European regulatory milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HCA Healthcare (HCA) Q2 Earnings Surpass Estimates

HCA (HCA) delivered earnings and revenue surprises of +0.26% and 0.00%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

TDOC, AMWL Stocks Retreat After OpenAI Lets Users Link Medical Records To ChatGPT 

Equity

A new ChatGPT feature allows users to securely connect personal health data, enabling more personalized, context-aware responses to everyday health questions.


Teladoc (TDOC) Gains As Market Dips: What You Should Know

The latest trading day saw Teladoc (TDOC) settling at $9.65, representing a +2.33% change from its previous close.

Teladoc (TDOC) Rises Higher Than Market: Key Facts

Teladoc (TDOC) closed the most recent trading day at $9.21, moving +1.54% from the previous trading session.

Teladoc in the Spotlight as Investors Refocus on Company's Walmart Better Care Partnership

Teladoc Health Inc. (NYSE: TDOC) shares are trending Wednesday as investors take a fresh look at the company.read more...

Hims & Hers Health vs. Teladoc Health: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsHims & Hers Health continues to drive impressive growth through its subscription-based consumer wellness platform...

Teladoc (TDOC) Stock Falls Amid Market Uptick: What Investors Need to Know

The latest trading day saw Teladoc (TDOC) settling at $8.48, representing a -2.42% change from its previous close.

Teladoc (TDOC) Moves 6.1% Higher: Will This Strength Last?

Teladoc (TDOC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

SenesTech Appoints Jack Karabees as Executive Vice President of Sales

SenesTech Appoints Jack Karabees as Executive Vice President of Sales SenesTech Appoints Jack Karabees as Executive Vice President of Sales PR Newswire SURPRISE, Ariz., June 29, 2026 Veteran enterprise sales executive brings decades of experience scaling companies and leading successful commercial...

Teladoc (TDOC) Ascends While Market Falls: Some Facts to Note

Teladoc (TDOC) concluded the recent trading session at $7.81, signifying a +1.56% move from its prior day's close.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

The Fed's July 28-29 meeting has markets debating a hold versus a hike, not a cut, with CME FedWatch pricing roughly a 65% chance of no change and rising odds of a September rate increase amid inflation running well above the 2% target. What do you expect the Fed to decide? Drop a comment with when you expect the first cut/hike to be.

What do you expect the Fed to decide at its FOMC meeting?  
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

TDOCTeladoc Health Inc

Latest TDOC News